John Southard, MD
Pulmonary Disease · Council Bluffs, IANPI 1104967090
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $150,636 of the $183,951 with a category attached, or 81.9%. GSK accounts for 70.7% of it on its own, with 45 other manufacturers making up the rest. Reporting peaked in 2023 at $51,984 and has fallen 89.3% since, to $5,580 in 2025. Among pulmonary disease clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 806 payments — averaging $228.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$130K
- Mylan Specialty L.p.$35K
- AstraZeneca$7K
- Viatris Specialty LLC$4K
- Chiesi USA, Inc.$2K
- Boehringer Ingelheim$613
- plus $6K from 40 others
Across 10 payments — averaging $6124.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shionogi Inc$41K
- GSK$9K
- Chiesi USA, Inc.$7K
- AstraZeneca$4K
What the payments were for
- Consulting fees$13,2517%
- Speaking & faculty fees$150,63682%
- Travel & lodging$7,3334%
- Food & beverage$12,2777%
- Education$4300%
- Entertainment$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$183,951 in reported general payments places this provider in the 95th percentile of 110 pulmonary disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 753 | $571,280 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 13 | $349,019 |
| OfevNintedanib Esylate | 24 | $296,853 |
| Breo ElliptaFluticasone/Vilanterol | 284 | $134,756 |
| Dupixent PenDupilumab | 31 | $130,391 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 126 | $92,354 |
| Dupixent SyringeDupilumab | 21 | $85,574 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $75,337 |
| Pirfenidone | 35 | $58,878 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 67 | $46,821 |
| DelstrigoDoravirine/Lamivu/Tenofov Diso | 11 | $28,603 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 31 | $19,163 |
| Spiriva RespimatTiotropium Bromide | 14 | $13,104 |
| Incruse ElliptaUmeclidinium Bromide | 26 | $12,002 |
| Epinephrine | 52 | $8,073 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $130,107 | $770,9961,151 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $613 | $329,12069 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $7,095 | $98,679154 claims |
| Grifols USA, LLCProlastin C | $250 | $75,33712 claims |
| MerckDelstrigo | $113 | $28,60311 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $30 | $3412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 110 pulmonary disease providers in Iowa.
Other pulmonary disease in Council Bluffs
- Bryan KrajicekCouncil Bluffs$470K
- Sumit MukherjeeCouncil Bluffs$264K
- Dustin McCannWest Des Moines$67K
- Alejandro ComellasIowa City$54K
- Matthew TrumpWest Des Moines$41K
- Brian WittDavenport$19K
- Shrey VelaniDes Moines$18K
- James MallenWest Des Moines$16K
- Neil HorningDes Moines$15K
- Anand KommuriDavenport$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.